BAROnova
BAROnova is a clinical-stage medical-device company founded in 2006 that develops non-surgical, non-pharmacologic devices designed to induce weight loss. The company is headquartered in Goleta, California.
- Company typePrivate
- Founded2006
- HeadquartersGoleta, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BAROnova does
BAROnova is a clinical-stage medical-device company founded in 2006 and headquartered in Goleta, California. The company's mission, as described in its firmographic profile, is to develop non-surgical, non-pharmacologic devices designed to induce weight loss, positioning it in the obesity-treatment market with a therapeutic modality that sits adjacent to bariatric surgery and weight-loss pharmacotherapy rather than competing head-on with either.
The company has been financed primarily through venture capital with strategic corporate participation. Public funding records show approximately $85.9 million raised across seven disclosed rounds between January 2006 and September 2016, comprising both equity Series-3 rounds and one venture-debt facility. The investor base spans dedicated healthcare VCs (Arboretum Ventures, Highland Capital Partners, ONSET Ventures, Sante Ventures, Lumira Ventures, Longitude Capital, Delos Capital) and two notable strategic corporate investors - Allergan (lead in the 2008 round) and Boston Scientific (lead in the 2013 round). The 2015 Series 3 at $36.5 million was the largest single equity raise in the company's history.
BAROnova operates with a headcount of 11-50 employees, consistent with a lean clinical-stage medical-device company in the R&D and regulatory pathway phase. Its publicly listed management includes a CEO & President (Hugh Narciso), a President & CEO (David Thrower), and an SVP of Clinical Affairs & Regulatory Affairs (Lian Cunningham). The company's website (baronova.com) presents only a loader/verification page in the scraped data, typical of a private clinical-stage entity with limited public-facing communications. Pricing, reimbursement strategy, distribution channels, payer mix, customer segments, and revenue mechanics are not disclosed in the available input, consistent with a pre-commercial posture.
BAROnova firmographics
Firmographics- Name
- BAROnova
- Website
- https://baronova.com
- Company type
- Private
- Founded year
- 2006
- Headcount range
- 11–50 employees
- Short description
- BAROnova is a clinical-stage medical-device company founded in 2006 that develops non-surgical, non-pharmacologic devices designed to induce weight loss. The company is headquartered in Goleta, California.
- Ownership category
- akta.pro rank
BAROnova industry classification
Industry- Product category
- Obesity Treatment Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Obesity Medicine & Weight Management (HLAKADAL)
Keywords
Where BAROnova is headquartered
LocationHeadquarters
- HQ city
- Goleta
- HQ country
- United States
- HQ region
- North America
Markets served
BAROnova business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
BAROnova product offering
Product offeringCore offering
BAROnova is a clinical-stage medical device company developing non-surgical, non-pharmacologic devices designed to induce weight loss. The company focuses on creating proprietary gastrointestinal implant-based technologies intended for the treatment of obesity as an alternative to surgical and pharmaceutical interventions.
Differentiator
Problem solved
Functional benefit
Products and services
- Non-surgical, non-pharmacologic weight loss device
Companies that use BAROnova
Customer profileIdeal customer profiles1 record
BAROnova technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
BAROnova partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
BAROnova competitors and assessment
Company assessmentDirect peers
- Allurion Technologies: Developer of the Allurion (formerly Elipse) swallowable, procedure-less gastric balloon for weight loss; directly comparable as a non-surgical, non-pharmacologic weight-loss device targeting the same patient and physician segments.
- Apollo Endosurgery: Markets the Orbera intragastric balloon system for endoscopic weight-loss intervention; directly comparable as an approved, commercially available weight-loss device competing for the same bariatric and gastroenterology channels.
- Spatz FGIA: Maker of the Spatz3 adjustable intragastric balloon, an endoscopic weight-loss device; directly comparable mechanism and target market as a non-pharmacologic obesity device.
- Obalon Therapeutics: Developed the Obalon gas-filled intragastric balloon system for non-surgical weight loss; directly comparable as a swallowable/non-surgical weight-loss device targeting similar patient populations.
- Gelesis: Developed Plenity, an oral hydrogel capsule for weight management; comparable as a non-surgical, non-procedural weight-loss intervention competing for the same physician-prescribed obesity category.
- ReShape Medical: Developed the ReShape intragastric balloon and later the vBloc neurometabolic system (via EnteroMedics acquisition); directly comparable as a non-pharmacologic weight-loss device company.
- EnteroMedics: Developer of vBloc, an implantable neurometabolic device for obesity treatment; comparable as a medical-device approach to obesity positioned between drugs and surgery.
- AspireAssist (Aspire Bariatrics): Developer of the AspireAssist percutaneous gastrostomy aspiration device for weight loss; comparable as an interventional, non-pharmacologic obesity device targeting similar patient demographics.
Broad incumbents
- Boston Scientific: Large-cap medical-device incumbent and prior investor in BAROnova; overlapping interests in endoscopic and bariatric interventions, providing a strategic exit reference point and a broad incumbent with adjacent weight-loss capabilities.
- Allergan (now AbbVie): Earlier investor in BAROnova with historical bariatric and obesity franchises (e.g., Lap-Band via Apollo Endosurgery); relevant incumbent for strategic benchmarking and as an acquirer reference in the obesity-device category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
BAROnova social profiles
Digital presenceBAROnova financial estimates
Financial estimateRevenue estimate
Valuation estimate
BAROnova leadership team
Management profileNumber of profiles
Profiles3 records
BAROnova funding detail
Funding detailFunding overview
Funding rounds7 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BAROnova M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BAROnova
What does BAROnova do?
BAROnova is a clinical-stage medical device company developing non-surgical, non-pharmacologic devices designed to induce weight loss. The company focuses on creating proprietary gastrointestinal implant-based technologies intended for the treatment of obesity as an alternative to surgical and pharmaceutical interventions.
When was BAROnova founded?
BAROnova was founded in 2006. It employs 11 to 50 people.
Where is BAROnova based?
BAROnova is headquartered in Goleta, United States, in the North America region.
Who are BAROnova's main competitors?
Direct peers on record are Allurion Technologies, Apollo Endosurgery, Spatz FGIA, Obalon Therapeutics, Gelesis, ReShape Medical, EnteroMedics and AspireAssist (Aspire Bariatrics). Broad incumbents are Boston Scientific and Allergan (now AbbVie).
Does BAROnova have an API?
No public API is recorded for BAROnova.
What industry is BAROnova in?
BAROnova's product category is Obesity Treatment Medical Devices. Its primary akta.pro industry code is HLAKADAL, Obesity Medicine & Weight Management. Its NAICS code is 3391 and its SIC code is 3841.